Care
The industrial giant plans to retain a stake of almost 20% in GE Healthcare.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
The scheme is being run in partnership with government technology firm PUBLIC.
The pair aim to make AI-enhanced diagnostics accessible beyond hospital settings.
The plan, built with Trustmark Health Benefits, is centered on Teladoc’s primary care offering, recently made available to payers.
Also: Pediatric sleep app Huckleberry raises $12.5 million, and illumigyn, maker of a platform for remote gynecological imaging, brings in $33 million.
The mobile platform allows users to access pharmacy services and make appointments, search for drug options and get manufacturer coupons.
A new app which collates older people’s health indicators and monitors for flu symptoms supports nurses and carers to make remote diagnoses and treat patients in their homes, reducing hospitalisations.